Text

Innovating Out Of Crisis

---

Abstractrn:rn“Innovating Out of Crisis”rnShigetaka Komorirn/rnPresented by rnLimor Ben Asher FUJIFILM HuntrnUSArnOver the last decade, KomorirnShigetaka, FUJIFILM Corp Chairman diversified into new businesses as demand for the company’s trademark green photorn-rnfilm boxes plummeted and archrival Eastman Kodak Co. went bankrupt. Fujifilm this year reported record profit of 119 billion yen ($950 million) and analysts expect a jump of more than 5 percent by next spring. Last month it announced a 100 billion yen share buyback rn--rnits largest ever.rnWith plans to spend more than 400 billion yen on acquisitions by 2017, add new product lines and make a more aggressive push into health care. Among the new ideas he is testing: a filter for natural gas purification and stem cells capable of regenerating tissue in the human body.rnrn“I wouldn’t say we’ve won yet,” said Komori, who is also chief executive officer. “It’s difficult for any company to declare that because everything is changing so fast. We’re going to keep going.” Other Japanese tech companies are also trying to reinvent themselves. Walkman inventor Sony Corp. has morphed into a supplier of camera sensors for smartphone makers. Panasonic Corp. has branched off into supplying batteries to Tesla Motors Inc.rnrnKomori’s efforts began a decade ago, when the ascent of digital cameras and smartphones began cannibalizing film sales. That led him to push the company’s engineers and executives to take a long, close look at the technology that helps perfect the dozens of layers and compounds in photographic film. Fujifilm went on to reapply that expertise to new businesses, including skin care and film that holds LCD screens together. The company made deals, including the acquisition of drugmaker Toyama Chemical Co., maker of an antiviral drug that was used by some Ebola patients last year. Photocopier machines and printers became its largest source of revenue after the slump in film. While these are likely to remain the biggest businesses, Komori sees the newer biotechnology and pharmaceutical operations as future drivers of growth.rnrnWith his investments in unproven new areas, Komori faces risks: the possibility of unsuccessful products and a long wait for any payout. “It’s like in the military,” Komori said. “Leaders need to be briefing their men every day on what is going on and what rnneeds to be done, and make sure everyone acts all the way down.” Part of the challenge is to create research teams willing to try new ideas. Scientist Tomoko Tashiro, who had been developing molecules for preserving photographs, came back from maternity leave in 2005 to find that she had been reassigned. She was asked to look into applying the same technology to skin. “It was bewildering at first,” Tashiro said. “But soon after I could see how much value we could add.”rnrnAcross the world in Tilburg, the Netherlands, Akira Kase, who now heads Fujifilm’s biopharmaceutical initiatives, remembers many brainstorming sessions with Dutch colleagues. A decade later, one of their ideas, a filter for the natural gas purification process to reduce energy costs, will soon come on the market. Even photo sales which bottomed out in 2011 are beginning to pick up again, driven by the growing popularity of Fujifilm’s instant cameras and printers, which have become ubiquitous at weddings the world over.

---

Ketersediaan

B01351

Tersedia

Informasi Detail

Judul Seri

-

No. Panggil

155.25 KOM i

Penerbit

Tokyo : Stone Bridge., 2015

Deskripsi Fisik

-

Bahasa

Indonesia

ISBN/ISSN

978-1-61172-023-5

Klasifikasi

155.25

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

Pertama

Subjek

-

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus login sebelum memberikan komentar